Abstract
Repair of DNA double-strand breaks (DSB)s is essential to the growth and survival of normal as well as cancer cells. Alteration of DSB repair properties in cancer cells can not only drive genomic instability, but also confer increased sensitivity to DSB-inducing agents. Development of agents that selectively inhibit DSB repair pathways will facilitate the design of therapeutic strategies that exploit the differences in DSB repair properties between normal and cancer cells. While mechanisms for classic non-homologous end joining (C-NHEJ) and Homologous recombination (HR) DSB repair pathways have been well studied in cancer, less is known about the alternative and highly error-prone, ALT-NHEJ pathway. Here, we discuss the mechanisms for ALT-NHEJ, alterations in this repair pathway in cancer, inhibition of ALT-NHEJ and future directions for cancer therapies that target this pathway.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Arnaudeau C, Lundin C, Helleday T (2001) DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. J Mol Biol 307(5):1235–1245
Audebert M, Salles B, Calsou P (2004) Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem 279(53):55117–55126
Audebert M, Salles B, Calsou P (2008) Effect of double-strand break DNA sequence on the PARP-1 NHEJ pathway. Biochem Biophys Res Commun 369(3):982–988
Augenlicht LH, Wadler S, Corner G, Richards C, Ryan L, Multani AS et al (1997) Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res 57(9):1769–1775
Baker VV, Borst MP, Dixon D, Hatch KD, Shingleton HM, Miller D (1990) c-myc amplification in ovarian cancer. Gynecol Oncol 38(3):340–342
Barton O, Naumann SC, Diemer-Biehs R, Kunzel J, Steinlage M, Conrad S et al (2014) Polo-like kinase 3 regulates CtIP during DNA double-strand break repair in G1. J Cell Biol 206(7):877–894
Bennardo N, Stark JM (2010) ATM limits incorrect end utilization during non-homologous end joining of multiple chromosome breaks. PLoS Genet 6(11):e1001194
Bennardo N, Cheng A, Huang N, Stark JM (2008) Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. PLoS Genet 4(6):e1000110
Bentley J, Diggle CP, Harnden P, Knowles MA, Kiltie AE (2004) DNA double strand break repair in human bladder cancer is error prone and involves microhomology-associated end-joining. Nucleic Acids Res 32(17):5249–5259
Berns EM, Klijn JG, van Putten WL, van Staveren IL, Portengen H, Foekens JA (1992a) c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res 52(5):1107–1113
Berns EM, Klijn JG, van Staveren IL, Portengen H, Noordegraaf E, Foekens JA (1992b) Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur J Cancer 28(2–3):697–700
Boulton SJ, Jackson SP (1996a) Identification of a Saccharomyces cerevisiae Ku80 homologue: roles in DNA double strand break rejoining and in telomeric maintenance. Nucleic Acids Res 24(23):4639–4648
Boulton SJ, Jackson SP (1996b) Saccharomyces cerevisiae Ku70 potentiates illegitimate DNA double-strand break repair and serves as a barrier to error-prone DNA repair pathways. EMBO J 15(18):5093–5103
Boultwood J, Wyllie FS, Williams ED, Wynford-Thomas D (1988) N-myc expression in neoplasia of human thyroid C-cells. Cancer Res 48(14):4073–4077
Brunet E, Simsek D, Tomishima M, DeKelver R, Choi VM, Gregory P et al (2009) Chromosomal translocations induced at specified loci in human stem cells. Proc Natl Acad Sci U S A 106(26):10620–10625
Ceccaldi R, Liu JC, Amunugama R, Hajdu I, Primack B, Petalcorin MI et al (2015) Homologous-recombination-deficient tumours are dependent on Poltheta-mediated repair. Nature 518(7538):258–262
Chen CH, Shen J, Lee WJ, Chow SN (2005) Overexpression of cyclin D1 and c-Myc gene products in human primary epithelial ovarian cancer. Int J Gynecol Cancer 15(5):878–883
Chen X, Zhong S, Zhu X, Dziegielewska B, Ellenberger T, Wilson GM et al (2008) Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair. Cancer Res 68(9):3169–3177
Chen H, Lisby M, Symington LS (2013) RPA coordinates DNA end resection and prevents formation of DNA hairpins. Mol Cell 50(4):589–600
Cheng Q, Barboule N, Frit P, Gomez D, Bombarde O, Couderc B et al (2011) Ku counteracts mobilization of PARP1 and MRN in chromatin damaged with DNA double-strand breaks. Nucleic Acids Res 39(22):9605–9619
Chiang C, Jacobsen JC, Ernst C, Hanscom C, Heilbut A, Blumenthal I et al (2012) Complex reorganization and predominant non-homologous repair following chromosomal breakage in karyotypically balanced germline rearrangements and transgenic integration. Nat Genet 44(4):390–397. S1
Cotner-Gohara E, Kim IK, Tomkinson AE, Ellenberger T (2008) Two DNA-binding and nick recognition modules in human DNA ligase III. J Biol Chem 283(16):10764–10772
Cotner-Gohara E, Kim IK, Hammel M, Tainer JA, Tomkinson AE, Ellenberger T (2010) Human DNA ligase III recognizes DNA ends by dynamic switching between two DNA-bound states. Biochemistry 49(29):6165–6176
Critchlow SE, Jackson SP (1998) DNA end-joining: from yeast to man. Trends Biochem Sci 23(10):394–398
De Lorenzo SB, Patel AG, Hurley RM, Kaufmann SH (2013) The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells. Front Oncol 3:228
DeFazio LG, Stansel RM, Griffith JD, Chu G (2002) Synapsis of DNA ends by DNA-dependent protein kinase. EMBO J 21(12):3192–3200
Della-Maria J, Zhou Y, Tsai MS, Kuhnlein J, Carney JP, Paull TT et al (2011) Human Mre11/human Rad50/Nbs1 and DNA ligase IIIalpha/XRCC1 protein complexes act together in an alternative nonhomologous end joining pathway. J Biol Chem 286(39):33845–33853
Deng SK, Chen H, Symington LS (2014a) Replication protein A prevents promiscuous annealing between short sequence homologies: implications for genome integrity. BioEssays 37(3):305–313
Deng SK, Gibb B, de Almeida MJ, Greene EC, Symington LS (2014b) RPA antagonizes microhomology-mediated repair of DNA double-strand breaks. Nat Struct Mol Biol 21(4):405–412
Difilippantonio MJ, Zhu J, Chen HT, Meffre E, Nussenzweig MC, Max EE et al (2000) DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature 404(6777):510–514
Eilers M, Schirm S, Bishop JM (1991) The MYC protein activates transcription of the alpha-prothymosin gene. EMBO J 10(1):133–141
Ellenberger T, Tomkinson AE (2008) Eukaryotic DNA ligases: structural and functional insights. Annu Rev Biochem 77:313–338
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917–921
Feldmann E, Schmiemann V, Goedecke W, Reichenberger S, Pfeiffer P (2000) DNA double-strand break repair in cell-free extracts from Ku80-deficient cells: implications for Ku serving as an alignment factor in non-homologous DNA end joining. Nucleic Acids Res 28(13):2585–2596
Fernandez-Vidal A, Guitton-Sert L, Cadoret JC, Drac M, Schwob E, Baldacci G et al (2014) A role for DNA polymerase theta in the timing of DNA replication. Nat Commun 5:4285
Fleming WH, Hamel A, MacDonald R, Ramsey E, Pettigrew NM, Johnston B et al (1986) Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res 46(3):1535–1538
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123–134
Frank KM, Sharpless NE, Gao Y, Sekiguchi JM, Ferguson DO, Zhu C et al (2000) DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via the p53 pathway. Mol Cell 5(6):993–1002
Gao Y, Chaudhuri J, Zhu C, Davidson L, Weaver DT, Alt FW (1998) A targeted DNA-PKcs-null mutation reveals DNA-PK-independent functions for KU in V(D)J recombination. Immunity 9(3):367–376
Gao Y, Ferguson DO, Xie W, Manis JP, Sekiguchi J, Frank KM et al (2000) Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. Nature 404(6780):897–900
Ghezraoui H, Piganeau M, Renouf B, Renaud JB, Sallmyr A, Ruis B et al (2014) Chromosomal translocations in human cells are generated by canonical nonhomologous end-joining. Mol Cell 55(6):829–842
Goff JP, Shields DS, Seki M, Choi S, Epperly MW, Dixon T et al (2009) Lack of DNA polymerase theta (POLQ) radiosensitizes bone marrow stromal cells in vitro and increases reticulocyte micronuclei after total-body irradiation. Radiat Res 172(2):165–174
Gottlieb TM, Jackson SP (1993) The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen. Cell 72(1):131–142
Guidos CJ, Williams CJ, Grandal I, Knowles G, Huang MT, Danska JS (1996) V(D)J recombination activates a p53-dependent DNA damage checkpoint in scid lymphocyte precursors. Genes Dev 10(16):2038–2054
Guirouilh-Barbat J, Huck S, Bertrand P, Pirzio L, Desmaze C, Sabatier L et al (2004) Impact of the KU80 pathway on NHEJ-induced genome rearrangements in mammalian cells. Mol Cell 14(5):611–623
Gunn A, Bennardo N, Cheng A, Stark JM (2011) Correct end use during end joining of multiple chromosomal double strand breaks is influenced by repair protein RAD50, DNA-dependent protein kinase DNA-PKcs, and transcription context. J Biol Chem 286(49):42470–42482
Hahnel PS, Enders B, Sasca D, Roos WP, Kaina B, Bullinger L et al (2014) Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy. Blood 123(15):2355–2366
Harada Y, Katagiri T, Ito I, Akiyama F, Sakamoto G, Kasumi F et al (1994) Genetic studies of 457 breast cancers. Clinicopathologic parameters compared with genetic alterations. Cancer 74(8):2281–2286
Hartlerode AJ, Scully R (2009) Mechanisms of double-strand break repair in somatic mammalian cells. Biochem J 423(2):157–168
Herold S, Herkert B, Eilers M (2009) Facilitating replication under stress: an oncogenic function of MYC? Nat Rev Cancer 9(6):441–444
Higgins GS, Prevo R, Lee YF, Helleday T, Muschel RJ, Taylor S et al (2010a) A small interfering RNA screen of genes involved in DNA repair identifies tumor-specific radiosensitization by POLQ knockdown. Cancer Res 70(7):2984–2993
Higgins GS, Harris AL, Prevo R, Helleday T, McKenna WG, Buffa FM (2010b) Overexpression of POLQ confers a poor prognosis in early breast cancer patients. Oncotarget 1(3):175–184
Hochegger H, Dejsuphong D, Fukushima T, Morrison C, Sonoda E, Schreiber V et al (2006) Parp-1 protects homologous recombination from interference by Ku and ligase IV in vertebrate cells. EMBO J 25(6):1305–1314
Hogg M, Sauer-Eriksson AE, Johansson E (2012) Promiscuous DNA synthesis by human DNA polymerase theta. Nucleic Acids Res 40(6):2611–2622
Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM et al (2012) MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med 209(4):679–696
Jenkins RB, Qian J, Lieber MM, Bostwick DG (1997) Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57(3):524–531
Kabotyanski EB, Gomelsky L, Han JO, Stamato TD, Roth DB (1998) Double-strand break repair in Ku86- and XRCC4-deficient cells. Nucleic Acids Res 26(23):5333–5342
Karlsson A, Deb-Basu D, Cherry A, Turner S, Ford J, Felsher DW (2003) Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc Natl Acad Sci U S A 100(17):9974–9979
Kawamura K, Bahar R, Seimiya M, Chiyo M, Wada A, Okada S et al (2004) DNA polymerase theta is preferentially expressed in lymphoid tissues and upregulated in human cancers. Int J Cancer 109(1):9–16
Keller KL, Overbeck-Carrick TL, Beck DJ (2001) Survival and induction of SOS in Escherichia coli treated with cisplatin, UV-irradiation, or mitomycin C are dependent on the function of the RecBC and RecFOR pathways of homologous recombination. Mutat Res 486(1):21–29
Kent T, Chandramouly G, McDevitt SM, Ozdemir AY, Pomerantz RT (2015) Mechanism of microhomology-mediated end-joining promoted by human DNA polymerase theta. Nat Struct Mol Biol 22(3):230–237
Khanna KK, Jackson SP (2001) DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 27(3):247–254
Kim MY, Zhang T, Kraus WL (2005) Poly(ADP-ribosyl)ation by PARP-1: ‘PAR-laying’ NAD+ into a nuclear signal. Genes Dev 19(17):1951–1967
Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T et al (2015) FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res 21(19):4257–4261
Kozma L, Kiss I, Szakall S, Ember I (1994) Investigation of c-myc oncogene amplification in colorectal cancer. Cancer Lett 81(2):165–169
Krasner DS, Daley JM, Sung P, Niu H (2015) Interplay between Ku and replication protein A in the restriction of Exo1-mediated DNA break end resection. J Biol Chem 290(30):18806–18816
Langelier MF, Pascal JM (2013) PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis. Curr Opin Struct Biol 23(1):134–143
Lee SE, Mitchell RA, Cheng A, Hendrickson EA (1997) Evidence for DNA-PK-dependent and -independent DNA double-strand break repair pathways in mammalian cells as a function of the cell cycle. Mol Cell Biol 17(3):1425–1433
Lemee F, Bergoglio V, Fernandez-Vidal A, Machado-Silva A, Pillaire MJ, Bieth A et al (2010) DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability. Proc Natl Acad Sci U S A 107(30):13390–13395
Li Y, Gao X, Wang JY (2011) Comparison of two POLQ mutants reveals that a polymerase-inactive POLQ retains significant function in tolerance to etoposide and gamma-irradiation in mouse B cells. Genes Cells 16(9):973–983
Lieber MR (2008) The mechanism of human nonhomologous DNA end joining. J Biol Chem 283(1):1–5
Lieber MR, Ma Y, Pannicke U, Schwarz K (2003) Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol 4(9):712–720
Lieber MR, Yu K, Raghavan SC (2006) Roles of nonhomologous DNA end joining, V(D)J recombination, and class switch recombination in chromosomal translocations. DNA Repair (Amst) 5(9–10):1234–1245
Lim DS, Vogel H, Willerford DM, Sands AT, Platt KA, Hasty P (2000) Analysis of ku80-mutant mice and cells with deficient levels of p53. Mol Cell Biol 20(11):3772–3780
Little CD, Nau MM, Carney DN, Gazdar AF, Minna JD (1983) Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306(5939):194–196
Lupo B, Trusolino L (2014) Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited. Biochim Biophys Acta 1846(1):201–215
Makharashvili N, Tubbs AT, Yang SH, Wang H, Barton O, Zhou Y et al (2014) Catalytic and noncatalytic roles of the CtIP endonuclease in double-strand break end resection. Mol Cell 54(6):1022–1033
Mansour WY, Rhein T, Dahm-Daphi J (2010) The alternative end-joining pathway for repair of DNA double-strand breaks requires PARP1 but is not dependent upon microhomologies. Nucleic Acids Res 38(18):6065–6077
Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de Murcia J, de Murcia G (1998) XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 18(6):3563–3571
Mateos-Gomez PA, Gong F, Nair N, Miller KM, Lazzerini-Denchi E, Sfeir A (2015) Mammalian polymerase theta promotes alternative NHEJ and suppresses recombination. Nature 518(7538):254–257
Mehta A, Haber JE (2014) Sources of DNA double-strand breaks and models of recombinational DNA repair. Cold Spring Harb Perspect Biol 6(9):a016428
Menissier-de Murcia J, Molinete M, Gradwohl G, Simonin F, de Murcia G (1989) Zinc-binding domain of poly(ADP-ribose)polymerase participates in the recognition of single strand breaks on DNA. J Mol Biol 210(1):229–233
Michels J, Vitale I, Saparbaev M, Castedo M, Kroemer G (2014) Predictive biomarkers for cancer therapy with PARP inhibitors. Oncogene 33(30):3894–3907
Mimitou EP, Symington LS (2008) Sae2, Exo1 and Sgs1 collaborate in DNA double-strand break processing. Nature 455(7214):770–774
Mitani S, Kamata H, Fujiwara M, Aoki N, Tango T, Fukuchi K et al (2001) Analysis of c-myc DNA amplification in non-small cell lung carcinoma in comparison with small cell lung carcinoma using polymerase chain reaction. Clin Exp Med 1(2):105–111
Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH et al (2012) Trapping of PARP1 and PARP2 by clinical PARP Inhibitors. Cancer Res 72(21):5588–5599
Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S et al (2013) Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 13(2):433–443
Muvarak N, Kelley S, Robert C, Baer MR, Perrotti D, Gambacorti-Passerini C et al (2015) c-MYC generates repair errors via increased transcription of alternative-NHEJ fdactors, LIG3 and PARP1, in tyrosine kinase-activated leukemias. Mol Cancer Res 13(4):699–712
Nacht M, Strasser A, Chan YR, Harris AW, Schlissel M, Bronson RT et al (1996) Mutations in the p53 and SCID genes cooperate in tumorigenesis. Genes Dev 10(16):2055–2066
Negrini S, Gorgoulis VG, Halazonetis TD (2010) Genomic instability—an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11(3):220–228
Nesbit CE, Tersak JM, Prochownik EV (1999) MYC oncogenes and human neoplastic disease. Oncogene 18(19):3004–3016
New JH, Sugiyama T, Zaitseva E, Kowalczykowski SC (1998) Rad52 protein stimulates DNA strand exchange by Rad51 and replication protein A. Nature 391(6665):407–410
Oh S, Harvey A, Zimbric J, Wang Y, Nguyen T, Jackson PJ et al (2014) DNA ligase III and DNA ligase IV carry out genetically distinct forms of end joining in human somatic cells. DNA Repair (Amst) 21:97–110
Orta ML, Hoglund A, Calderon-Montano JM, Dominguez I, Burgos-Moron E, Visnes T et al (2014) The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesions. Nucleic Acids Res 42(14):9108–9120
Patel AG, Sarkaria JN, Kaufmann SH (2011) Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A 108(8):3406–3411
Pergola F, Zdzienicka MZ, Lieber MR (1993) V(D)J recombination in mammalian cell mutants defective in DNA double-strand break repair. Mol Cell Biol 13(6):3464–3471
Petalcorin MI, Sandall J, Wigley DB, Boulton SJ (2006) CeBRC-2 stimulates D-loop formation by RAD-51 and promotes DNA single-strand annealing. J Mol Biol 361(2):231–242
Peterson SE, Li Y, Wu-Baer F, Chait BT, Baer R, Yan H et al (2013) Activation of DSB processing requires phosphorylation of CtIP by ATR. Mol Cell 49(4):657–667
Pillaire MJ, Selves J, Gordien K, Gourraud PA, Gentil C, Danjoux M et al (2010) A ‘DNA replication’ signature of progression and negative outcome in colorectal cancer. Oncogene 29(6):876–887
Plummer R, Lorigan P, Steven N, Scott L, Middleton MR, Wilson RH et al (2013) A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol 71(5):1191–1199
Prasad R, Longley MJ, Sharief FS, Hou EW, Copeland WC, Wilson SH (2009) Human DNA polymerase theta possesses 5′-dRP lyase activity and functions in single-nucleotide base excision repair in vitro. Nucleic Acids Res 37(6):1868–1877
Rassool FV, Tomkinson AE (2010) Targeting abnormal DNA double strand break repair in cancer. Cell Mol Life Sci 67(21):3699–3710
Roncalli M, Viale G, Grimelius L, Johansson H, Wilander E, Alfano RM et al (1994) Prognostic value of N-myc immunoreactivity in medullary thyroid carcinoma. Cancer 74(1):134–141
Roth DB, Wilson JH (1986) Nonhomologous recombination in mammalian cells: role for short sequence homologies in the joining reaction. Mol Cell Biol 6(12):4295–4304
Saleh-Gohari N, Bryant HE, Schultz N, Parker KM, Cassel TN, Helleday T (2005) Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Mol Cell Biol 25(16):7158–7169
Sallmyr A, Tomkinson AE, Rassool FV (2008) Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks. Blood 112(4):1413–1423
Sartori AA, Lukas C, Coates J, Mistrik M, Fu S, Bartek J et al (2007) Human CtIP promotes DNA end resection. Nature 450(7169):509–514
Satoh MS, Lindahl T (1992) Role of poly(ADP-ribose) formation in DNA repair. Nature 356(6367):356–358
Seki M, Marini F, Wood RD (2003) POLQ (Pol theta), a DNA polymerase and DNA-dependent ATPase in human cells. Nucleic Acids Res 31(21):6117–6126
Seki M, Masutani C, Yang LW, Schuffert A, Iwai S, Bahar I et al (2004) High-efficiency bypass of DNA damage by human DNA polymerase Q. EMBO J 23(22):4484–4494
Sharief FS, Vojta PJ, Ropp PA, Copeland WC (1999) Cloning and chromosomal mapping of the human DNA polymerase theta (POLQ), the eighth human DNA polymerase. Genomics 59(1):90–96
Sharpless NE, Ferguson DO, O'Hagan RC, Castrillon DH, Lee C, Farazi PA et al (2001) Impaired nonhomologous end-joining provokes soft tissue sarcomas harboring chromosomal translocations, amplifications, and deletions. Mol Cell 8(6):1187–1196
Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R et al (2013) BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res 19(18):5003–5015
Shen Y, Aoyagi-Scharber M, Wang B (2015) Trapping Poly(ADP-Ribose) Polymerase. J Pharmacol Exp Ther 353(3):446–457
Shima N, Munroe RJ, Schimenti JC (2004) The mouse genomic instability mutation chaos1 is an allele of Polq that exhibits genetic interaction with Atm. Mol Cell Biol 24(23):10381–10389
Simsek D, Jasin M (2010) Alternative end-joining is suppressed by the canonical NHEJ component Xrcc4-ligase IV during chromosomal translocation formation. Nat Struct Mol Biol 17(4):410–416
Simsek D, Brunet E, Wong SY, Katyal S, Gao Y, McKinnon PJ et al (2011a) DNA ligase III promotes alternative nonhomologous end-joining during chromosomal translocation formation. PLoS Genet 7(6):e1002080
Simsek D, Furda A, Gao Y, Artus J, Brunet E, Hadjantonakis AK et al (2011b) Crucial role for DNA ligase III in mitochondria but not in Xrcc1-dependent repair. Nature 471(7337):245–248
Smith J, Riballo E, Kysela B, Baldeyron C, Manolis K, Masson C et al (2003) Impact of DNA ligase IV on the fidelity of end joining in human cells. Nucleic Acids Res 31(8):2157–2167
Soni A, Siemann M, Grabos M, Murmann T, Pantelias GE, Iliakis G (2014) Requirement for Parp-1 and DNA ligases 1 or 3 but not of Xrcc1 in chromosomal translocation formation by backup end joining. Nucleic Acids Res 42(10):6380–6392
Sonnenblick A, de Azambuja E, Azim HA Jr, Piccart M (2015) An update on PARP inhibitors—moving to the adjuvant setting. Nat Rev Clin Oncol 12(1):27–41
Sturzenegger A, Burdova K, Kanagaraj R, Levikova M, Pinto C, Cejka P et al (2014) DNA2 cooperates with the WRN and BLM RecQ helicases to mediate long-range DNA end resection in human cells. J Biol Chem 289(39):27314–27326
Sugimura K, Takebayashi S, Taguchi H, Takeda S, Okumura K (2008) PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA. J Cell Biol 183(7):1203–1212
Takahashi Y, Kawate S, Watanabe M, Fukushima J, Mori S, Fukusato T (2007) Amplification of c-myc and cyclin D1 genes in primary and metastatic carcinomas of the liver. Pathol Int 57(7):437–442
Takata M, Sasaki MS, Sonoda E, Morrison C, Hashimoto M, Utsumi H et al (1998) Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J 17(18):5497–5508
Thomas L, Stamberg J, Gojo I, Ning Y, Rapoport AP (2004) Double minute chromosomes in monoblastic (M5) and myeloblastic (M2) acute myeloid leukemia: two case reports and a review of literature. Am J Hematol 77(1):55–61
Tobin LA, Robert C, Nagaria P, Chumsri S, Twaddell W, Ioffe OB et al (2012) Targeting abnormal DNA repair in therapy-resistant breast cancers. Mol Cancer Res 10(1):96–107
Tobin LA, Robert C, Rapoport AP, Gojo I, Baer MR, Tomkinson AE et al (2013) Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias. Oncogene 32(14):1784–1793
Tomkinson AE, Levin DS (1997) Mammalian DNA ligases. BioEssays 19(10):893–901
Truong LN, Li Y, Shi LZ, Hwang PY, He J, Wang H et al (2013) Microhomology-mediated end joining and homologous recombination share the initial end resection step to repair DNA double-strand breaks in mammalian cells. Proc Natl Acad Sci U S A 110(19):7720–7725
Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM et al (2002) c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 9(5):1031–1044
Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA et al (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8(5):393–406
Verkaik NS, Esveldt-van Lange RE, van Heemst D, Bruggenwirth HT, Hoeijmakers JH, Zdzienicka MZ et al (2002) Different types of V(D)J recombination and end-joining defects in DNA double-strand break repair mutant mammalian cells. Eur J Immunol 32(3):701–709
Vlach J, Hennecke S, Alevizopoulos K, Conti D, Amati B (1996) Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J 15(23):6595–6604
Wang H, Perrault AR, Takeda Y, Qin W, Iliakis G (2003) Biochemical evidence for Ku-independent backup pathways of NHEJ. Nucleic Acids Res 31(18):5377–5388
Wang M, Wu W, Rosidi B, Zhang L, Wang H, Iliakis G (2006) PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res 34(21):6170–6182
Wang H, Shi LZ, Wong CC, Han X, Hwang PY, Truong LN et al (2013) The interaction of CtIP and Nbs1 connects CDK and ATM to regulate HR-mediated double-strand break repair. PLoS Genet 9(2):e1003277
Windhofer F, Krause S, Hader C, Schulz WA, Florl AR (2008) Distinctive differences in DNA double-strand break repair between normal urothelial and urothelial carcinoma cells. Mutat Res 638(1–2):56–65
Xie A, Kwok A, Scully R (2009) Role of mammalian Mre11 in classical and alternative nonhomologous end joining. Nat Struct Mol Biol 16(8):814–818
Yaneva M, Kowalewski T, Lieber MR (1997) Interaction of DNA-dependent protein kinase with DNA and with Ku: biochemical and atomic-force microscopy studies. EMBO J 16(16):5098–5112
Yousefzadeh MJ, Wyatt DW, Takata K, Mu Y, Hensley SC, Tomida J et al (2014) Mechanism of suppression of chromosomal instability by DNA polymerase POLQ. PLoS Genet 10(10):e1004654
Yuan Y, Britton S, Delteil C, Coates J, Jackson SP, Barboule N et al (2015) Single-stranded DNA oligomers stimulate error-prone alternative repair of DNA double-strand breaks through hijacking Ku protein. Nucleic Acids Res 43(21):10264–10276
Yun MH, Hiom K (2009) CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle. Nature 459(7245):460–463
Zha S, Guo C, Boboila C, Oksenych V, Cheng HL, Zhang Y et al (2011) ATM damage response and XLF repair factor are functionally redundant in joining DNA breaks. Nature 469(7329):250–254
Znojek P, Willmore E, Curtin NJ (2014) Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase. Br J Cancer 111(7):1319–1326
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Nagaria, P., Rassool, F.V. (2018). Alternative Non-homologous End-Joining: Mechanisms and Targeting Strategies in Cancer. In: Pollard, J., Curtin, N. (eds) Targeting the DNA Damage Response for Anti-Cancer Therapy. Cancer Drug Discovery and Development. Humana Press, Cham. https://doi.org/10.1007/978-3-319-75836-7_15
Download citation
DOI: https://doi.org/10.1007/978-3-319-75836-7_15
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-75834-3
Online ISBN: 978-3-319-75836-7
eBook Packages: MedicineMedicine (R0)